Please provide your email address to receive an email when new articles are posted on . The use of a transcatheter mitral valve replacement system appears to be safe and effective in the treatment of ...

Medtronic plc (NYSE: MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral ...

First Report Investigation at TCT Published in JACC Shows Substantial Mitral Valve Regurgitation Reductions and Versatility of Dual-Stent Design "These early outcomes with the Intrepid TMVR System are ...

It remains early days for transcatheter mitral-valve replacement (TMVR) as a minimally invasive way to treat severe, mitral regurgitation (MR), but it's even earlier days for TMVR as an endovascular ...

DUBLIN and ORLANDO, Fla., Nov. 6, 2021 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today presented early data for its self-expanding Intrepid ™ transcatheter mitral ...

Half Moon Medical's Technology Now Ready for Evaluation in Early Feasibility Study Half Moon recently received U.S. FDA approval of an early feasibility study in patients with severe, symptomatic ...

Please provide your email address to receive an email when new articles are posted on . At 30 days, a group of 15 patients who underwent transfemoral transcatheter mitral valve replacement for ...

DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...